Today: 21 May 2026
Browse Category

NYSE:MRK 17 August 2025 - 29 November 2025

Merck & Co. (MRK) Stock News Today: Keytruda Wins, $9.2 Billion Cidara Deal and Fresh Highs — November 29, 2025

Merck & Co. (MRK) Stock News Today: Keytruda Wins, $9.2 Billion Cidara Deal and Fresh Highs — November 29, 2025

Merck shares closed at $104.83 on November 28, just below the 52-week high of $105.84 set earlier in the week after a Wells Fargo upgrade. The stock is up about 21% over the past month and 8% year-to-date. Scotia Capital and Level Four Advisory Services have trimmed their Merck holdings, according to new filings. Merck continues to warn investors about an unsolicited mini-tender offer from Tutanota LLC at $65 per share.
29 November 2025
·
Merck (MRK) Stock Rallies as Big Money Moves In and Dividend Rises – November 28, 2025 Update

Merck (MRK) Stock Rallies as Big Money Moves In and Dividend Rises – November 28, 2025 Update

Merck shares closed near $104.5 on Friday, close to a 52-week high, with market cap near $260 billion. Norges Bank disclosed a new $2.86 billion stake, while Groupama, SEB, and Boston Partners trimmed holdings. The stock jumped 21% in the past month, buoyed by new oncology approvals and bullish research. Merck’s trailing 12-month revenue stands at about $64 billion, with net income near $19 billion.
28 November 2025
···
Merck (MRK) Stock Today – November 26, 2025: Keytruda Wins, Analyst Upgrades and Big Money Buying Keep Shares Near Record Highs

Merck (MRK) Stock Today – November 26, 2025: Keytruda Wins, Analyst Upgrades and Big Money Buying Keep Shares Near Record Highs

Merck shares closed Wednesday at $105.3, just below their 52-week high of $105.84, after a 0.3% dip. The stock has surged about 40% since late May, fueled by FDA approval of Keytruda and Padcev for bladder cancer and strong Q3 earnings. Trading volume reached nearly 3.9 million shares. Merck’s market cap stands above $260 billion.
26 November 2025
··
Dow Jones Soars 664 Points as Fed Cut Hopes Ignite Dow 30 Rally — Merck and Home Depot Lead November 25, 2025 Surge

Dow Jones Soars 664 Points as Fed Cut Hopes Ignite Dow 30 Rally — Merck and Home Depot Lead November 25, 2025 Surge

The Dow Jones Industrial Average surged 664.18 points, or 1.43%, to 47,112.45 on Tuesday as investors bet the Federal Reserve will cut rates in December. The S&P 500 rose 0.91%, and the Nasdaq gained 0.67%. Softer retail sales, weaker consumer confidence, and a dip in Treasury yields fueled the move. Futures now price in over 80% odds of a December Fed rate cut.
25 November 2025
···
Merck (MRK) Stock Soars on FDA Keytruda Approval and Wells Fargo Upgrade – 25 November 2025

Merck (MRK) Stock Soars on FDA Keytruda Approval and Wells Fargo Upgrade – 25 November 2025

Merck shares rose nearly 4% to $104–$105 in early afternoon trading Tuesday, nearing a 52-week high, after the FDA approved Keytruda plus Padcev for certain bladder cancer patients. The rally, boosted by a Wells Fargo upgrade and strong broker commentary, helped drive the Dow more than 400 points higher. Over 11 million Merck shares changed hands by midday.
25 November 2025
··
Dow 30 Today (24 November 2025): Merck and Caterpillar Lead 200‑Point Dow Jones Rally on Fed Rate‑Cut Bets

Dow 30 Today (24 November 2025): Merck and Caterpillar Lead 200‑Point Dow Jones Rally on Fed Rate‑Cut Bets

The Dow Jones Industrial Average rose 202.86 points, or 0.44%, to 46,448.27 on Monday, as investors bet on a December Fed rate cut amid a government data blackout. The Nasdaq jumped 2.69% and the S&P 500 gained 1.55%. Treasury yields slipped to around 4.03%. The Bureau of Labor Statistics canceled the October CPI release due to the federal shutdown.
25 November 2025
·········
MRK Stock Today: Merck Jumps on Wells Fargo Upgrade and Keytruda Momentum (November 24, 2025)

MRK Stock Today: Merck Jumps on Wells Fargo Upgrade and Keytruda Momentum (November 24, 2025)

Merck shares climbed nearly 4% to around $101.40 by early afternoon Monday, nearing 2025 highs after Wells Fargo upgraded the stock to “Overweight” and raised its price target to $125. The move followed new FDA approvals and pipeline updates. Options activity surged, with call volume outpacing puts more than 3:1. Merck’s market cap stood at about $252 billion.
24 November 2025
··
Merck Stock Jumps on Wells Fargo Upgrade and New Keytruda Wins – MRK Today, November 24, 2025

Merck Stock Jumps on Wells Fargo Upgrade and New Keytruda Wins – MRK Today, November 24, 2025

Merck shares jumped about 4% to $101.97 on Monday after Wells Fargo upgraded the stock and raised its price target to $125. The move followed new data on Merck’s hematology pipeline, another FDA approval for Keytruda in bladder cancer, and increased institutional buying. MRK traded at its highest level since January, with technical indicators signaling overbought conditions.
24 November 2025
·
Merck (MRK) Stock Today: Mini‑Tender Warning, Dividend Hike and Drug Wins – 22 November 2025

Merck (MRK) Stock Today: Mini‑Tender Warning, Dividend Hike and Drug Wins – 22 November 2025

Merck urged shareholders to reject Tutanota LLC’s unsolicited mini-tender offer of $65 per share, about 25–32% below recent prices. The company raised its quarterly dividend to $0.85 and reported FDA approval for new Keytruda-based bladder cancer treatments. Merck stock traded near $97.76 Friday, up 2.9%, with a market cap of $243 billion.
22 November 2025
···
Merck (MRK) Jumps as Oral PCSK9 Data Power Momentum; New Keytruda Diagnostic Cleared — What’s Moving the Stock Today (Nov. 12, 2025)

Merck (MRK) Stock Today, Nov 18, 2025: Shares Jump on Winrevair Phase 2 Win as Cidara Deal Builds Flu Portfolio

Merck shares rose about 3%–4% Tuesday after the company said its drug Winrevair met the main goal in a Phase 2 study for combined post- and precapillary pulmonary hypertension due to heart failure with preserved ejection fraction. Merck plans to advance the drug to Phase 3 trials. The update follows last week’s $9.2 billion deal to acquire Cidara Therapeutics.
18 November 2025
··
Cidara Therapeutics (CDTX) Surges on Accelerated Flu Drug Trial – Key Updates for Investors

Merck’s $9.2 Billion Bid Sends Cidara Therapeutics (CDTX) Soaring 105% on November 14, 2025

Merck said it will acquire Cidara Therapeutics for $221.50 per share in cash, valuing the deal at about $9.2 billion. The offer represents a 109% premium to Cidara’s last closing price and sent CDTX shares up more than 100%. Both companies’ boards approved the deal, which is expected to close in early 2026 pending regulatory clearance. Merck aims to secure Cidara’s lead flu-prevention drug, CD388.
14 November 2025
··
5 NYSE Stocks to Watch Today (November 14, 2025): WMT, MRK, BMY, NSC, VRT

5 NYSE Stocks to Watch Today (November 14, 2025): WMT, MRK, BMY, NSC, VRT

Walmart shares dropped up to 3% after the company named John Furner as CEO, replacing Doug McMillon effective February 2026. Merck agreed to buy Cidara Therapeutics for $9.2 billion in cash, gaining access to a late-stage flu prevention drug. U.S. equity futures fell sharply as tech stocks continued to slide and traders lowered expectations for a near-term Fed rate cut.
14 November 2025
·····
Merck to Buy Cidara Therapeutics for $9.2 Billion in Bold Bet on Long‑Acting Flu Prevention

Merck to Buy Cidara Therapeutics for $9.2 Billion in Bold Bet on Long‑Acting Flu Prevention

Merck will acquire Cidara Therapeutics for about $9.2 billion, paying $221.50 per share in cash—a 109% premium to Cidara’s last close. The deal gives Merck rights to CD388, a Phase 3 long-acting flu prevention drug. Cidara shares doubled in pre-market trading. The transaction is expected to close in Q1 2026, pending approvals.
14 November 2025
···
Merck (MRK) Jumps as Oral PCSK9 Data Power Momentum; New Keytruda Diagnostic Cleared — What’s Moving the Stock Today (Nov. 12, 2025)

Merck (MRK) Jumps as Oral PCSK9 Data Power Momentum; New Keytruda Diagnostic Cleared — What’s Moving the Stock Today (Nov. 12, 2025)

Merck shares rose Wednesday after Phase 3 data showed its oral PCSK9 inhibitor enlicitide cut LDL-C by up to 59.7% and matched placebo for safety. The FDA also cleared Promega’s OncoMate MSI Dx as a companion diagnostic for Keytruda plus Lenvima in advanced endometrial carcinoma. JAMA published peer-reviewed results for enlicitide in HeFH.
12 November 2025
··
Dow Falls as Palantir Plunges – Is the AI Stock Boom Turning into a Bubble?

Dow Falls as Palantir Plunges – Is the AI Stock Boom Turning into a Bubble?

The Dow fell 0.5% Monday as UnitedHealth and Merck dropped, while the Nasdaq rose 0.5% on Amazon’s 4% jump after a $38 billion OpenAI deal. Palantir slid 8% despite beating revenue estimates, dragging other AI stocks lower. Wall Street leaders and Michael Burry warned of an AI-driven bubble and possible correction. Investors showed caution as weak manufacturing data and Fed policy jitters reversed early gains.
4 November 2025
·········
Merck (MRK) Stock Could Skyrocket: Key Drug Approvals & Analyst Targets Unveiled

Merck (MRK) Stock Dips on Earnings Beat — Will Pipeline Boost Spur a Rally?

Merck shares fell about 2% after hours Oct. 30 despite Q3 revenue of $17.28 billion and $2.58 adjusted EPS, both above estimates. Keytruda sales rose 10% to $8.1 billion. The company narrowed its 2025 sales outlook and raised profit guidance. Recent milestones include FDA approval of subcutaneous Keytruda and the $10 billion acquisition of Verona Pharma.
30 October 2025
···
Breakthrough Cures, Big Deals, and Global Health Alerts – Biotech & Health News Roundup (Aug 16–17, 2025)

Breakthrough Cures, Big Deals, and Global Health Alerts – Biotech & Health News Roundup (Aug 16–17, 2025)

Pfizer’s sickle cell drug inclacumab failed a Phase 3 trial, missing its main goal and deepening setbacks from its $5.4 billion Global Blood Therapeutics acquisition. In contrast, Pfizer and Merck’s Padcev-Keytruda combo improved survival in muscle-invasive bladder cancer. Novo Nordisk’s Wegovy won FDA approval for treating metabolic dysfunction-associated steatohepatitis.
17 August 2025
······
1 … 5 6 7 8

Stock Market Today

  • UK's FTSE 100 Declines Amid Middle East Tensions and Weak Data
    May 21, 2026, 8:11 AM EDT. The UK's FTSE 100 index slipped on Thursday, weighed down by disappointing economic data and concerns over a prolonged conflict in the Middle East. Investors grew cautious as fears of an extended war heightened market jitters, leading to a broad sell-off in blue-chip shares. The uncertainty surrounding geopolitical stability continues to impact market sentiment in London, reflecting worries about potential disruptions to global trade and energy supplies.

Latest articles

NIO Stock Rises Before Onvo L80 Launch as China EV Demand Faces a Hard Test

Nio slips to red, but margin draws investor attention

21 May 2026
Nio reported first-quarter revenue up 112.2% to RMB25.53 billion ($3.70 billion) and vehicle margin rising to 18.8%. The company posted a net loss of RMB332.1 million, compared to a profit in the previous quarter. Deliveries reached 83,465 vehicles, nearly doubling from a year earlier but down from the fourth quarter. Nio forecast second-quarter revenue and deliveries above analyst expectations.
IBM Stock Tumbles After Earnings Beat as Software Slowdown Reignites AI Fears

IBM, Rigetti, D-Wave gain after $2B quantum investment from Washington

21 May 2026
The Commerce Department will provide $2.013 billion in CHIPS Act incentives to nine quantum computing companies, taking minority, non-controlling equity stakes in each. IBM will receive $1 billion to establish a quantum foundry subsidiary, while GlobalFoundries gets $375 million. Shares of several quantum firms rose sharply in premarket trading following the announcement.
Walmart tops estimates, Wall Street reacts to warning

Walmart tops estimates, Wall Street reacts to warning

21 May 2026
Walmart reported first-quarter net revenue of $177.8 billion, up 7.3%, but shares fell 2% in premarket trading after it forecast weaker-than-expected second-quarter sales and profit. U.S. comparable sales rose 4.1%, and e-commerce jumped 26%. Fuel costs cut operating income by 2.5 percentage points. The company kept its full-year sales and profit outlook unchanged.
Go toTop